Patent ductus arteriosus with persistent pulmonary artery hypertension after transcatheter closure
Authors Feng JQ, Kong XQ, Sheng YH, Yang R
Received 9 May 2016
Accepted for publication 19 August 2016
Published 3 November 2016 Volume 2016:12 Pages 1609—1613
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Jianqi Feng,1,2 Xiangqing Kong,1 Yanhui Sheng,1 Rong Yang1
1Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 2Department of Cardiology, the Second Affiliated Hospital of XuZhou Medical University, XuZhou, Jiangsu, People’s Republic of China
Objectives: To observe the change in pulmonary artery systolic pressure (PASP) of patients with persistent pulmonary arterial hypertension (PAH) after patent ductus arteriosus (PDA) occlusion.
Background: After occlusion of PDA in patients with PAH, some patients still tend to suffer from persistent PAH.
Methods: A chest X-ray, an electrocardiogram, and an echocardiogram were performed on nine patients at 24 hours, 1 and 6 months, and 1 year serially.
Results: There was a significant fall (P<0.05) in mean PASP after occlusion (to 59.3±12.7 mmHg). However, the aortic pressure and systemic arterial oxygen saturation changed slightly (P>0.05). During the follow up, there was a further fall in the PASP in five patients (No 1, 5, 6, 7, and 8). Four patients (No 2, 3, 4, and 8) showed the evidence of worsening PAH and were treated with sildenafil. Patient 2 died from acute right heart failure after a period of 11 months from the time of transcatheter closure, triggered by pulmonary infection.
Conclusion: Some patients with borderline hemodynamic data with PDA and PAH can deteriorate or keep sustained PAH after PDA closure. The treatment of permanent closure to these patients must be cautious.
Keywords: patent ductus arteriosus (PDA), transcatheter closure (TCC), pulmonary artery hypertension, follow-up
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]